NASDAQ$SHC
Sotera Health Company · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Sotera Health reported Q4 2023 results with revenue increase driven by strong performance in Nordion and Sterigenics, offset by a slight decrease in Nelson Labs. Net income saw significant growth compared to the previous year due to a large legal reserve in 2022.
Sotera Health's Q4 2023 net revenues increased by 23.3% to $310 million compared to the same period last year. Net income was $39 million, a significant improvement from the net loss of $320 million in Q4 2022. Adjusted EBITDA increased by 28.7% to $167 million, and Adjusted EPS was $0.26, up by $0.01 per diluted share.
- Net revenues for Q4 2023 increased by 23.3% to $310 million.
- Net income for Q4 2023 was $39 million, compared to a net loss of $320 million in Q4 2022.
- Adjusted EBITDA for Q4 2023 increased by 28.7% to $167 million.
- Adjusted EPS for Q4 2023 was $0.26, an increase of $0.01 per diluted share.
Headline financials
Revenue & EPS history
Sotera Health · Revenue · Quarterly
$310M
Revenue by segment
Sotera Health · $263M total across 3 segments · Q3 2023
- Sterigenics$168M+6.7%64.0%
- Nelson Labs$54.7M-2.1%20.8%
- Nordion$40.1M+14.3%15.2%
Forward guidance
Sotera Health is providing its full-year 2024 outlook with net revenues and Adjusted EBITDA growth in the range of 4.0% to 6.0%.
Tailwinds
- Net revenues growth in the range of 4.0% to 6.0%.
- Adjusted EBITDA growth in the range of 4.0% to 6.0%.
- Tax rate applicable to Adjusted Net Income in the range of 31.5% to 34.5%.
- Adjusted EPS in the range of $0.67 to $0.75.
- Capital expenditures in the range of $205 million to $225 million.
Headwinds
- Interest Expense in the range of $170 million to $180 million.
- Uncertainties caused by changes to the regulatory landscape.
- Restructuring items.
- Certain fair value measurements.
- Impact of inflationary trends including their impact on energy prices and the supply of labor.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2023
-2.7%
Avg return
Earnings day
-3.0%
Avg return
5 days after
-2.4%
Avg return
30 days after
25%
6 / 24 earnings
Positive
+11.2%
Q2 2024
Best reaction
-15.9%
Q3 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.3% | +2.6% | +1.2% | |
| Q4 2025 | -0.5% | -7.1% | -22.6% | |
| Q3 2025 | -1.1% | -5.6% | -0.3% | |
| Q1 2025 | +5.2% | +11.7% | +6.4% | |
| Q4 2024 | -10.0% | -15.9% | -13.7% | |
| Q3 2024 | +2.0% | +1.8% | -17.9% | |
| Q2 2024 | +11.2% | +10.1% | +16.6% | |
| Q1 2024 | -2.2% | +1.8% | -0.8% | |
| Q4 2023 | -12.3% | -14.7% | -29.6% | |
| Q3 2023 | +1.2% | +5.8% | +10.6% | |
| Q2 2023 | -3.7% | -7.1% | -13.4% | |
| Q1 2023 | -7.5% | -7.9% | -9.2% | |
| Q4 2022 | -0.5% | +3.9% | +2.0% | |
| Q3 2022 | -10.6% | -7.7% | +28.6% | |
| Q2 2022 | +2.1% | +4.2% | -6.7% | |
| Q1 2022 | -2.8% | -5.4% | +3.7% | |
| Q4 2021 | -8.4% | -11.4% | -1.0% | |
| Q4 2019 | -8.4% | -11.4% | -1.0% | |
| Q3 2021 | -15.9% | -13.7% | -20.0% | |
| Q2 2021 | -0.7% | -6.3% | +1.0% | |
| Q2 2020 | -0.7% | -6.3% | +1.0% | |
| Q1 2021 | -5.4% | -3.4% | +3.5% | |
| Q1 2020 | -5.4% | -3.4% | +3.5% | |
| Q4 2020 | +8.9% | +13.6% | +1.4% | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro